Benitec Biopharma Inc. (BNTC) shareholders
Close on Nov 17, 2026Market cap $284.29MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Suvretta Capital Management, LLC Joint filing with Aaron Cowen (44.10%), Averill Master Fund, Ltd. (37.80%) and 1 more | 17,761,945 | 44.10% | 13D (active) amendment | Nov 7, 2025 |
| Aaron Cowen Joint filing with Suvretta Capital Management, LLC (49.90%), Averill Master Fund, Ltd. (44.47%) and 1 more | 15,623,659 | 49.90% | 13D (active) amendment | Mar 26, 2025 |
| Franklin Advisers, Inc. Joint filing with Franklin Resources, Inc. (18.10%) | 4,493,691 | 18.10% | 13G (passive) amendment | Dec 31, 2024 |
| Franklin Resources, Inc. Joint filing with Franklin Advisers, Inc. (10.60%) | 3,751,709 | 10.60% | 13G (passive) amendment | Dec 31, 2025 |
| Janus Henderson Group PLC Joint filing with Janus Henderson Biotech Innovation Master Fund Ltd (6.10%) | 3,382,836 | 9.99% | 13G (passive) amendment | Nov 28, 2025 |
| RA Capital Healthcare Fund, L.P. Joint filing with RA Capital Management, L.P. (5.50%), Peter Kolchinsky (5.50%) and 1 more | 1,850,000 | 5.50% | 13G (passive) | Nov 7, 2025 |
| Steven M. Oliveira Joint filing with Nemean Asset Management, LLC (8.39%) | 791,235 | 8.89% | 13G (passive) | Apr 22, 2024 |
| Adage Capital Management, L.P. Joint filing with Adage Capital Partners, L.P. (9.99%), Adage Capital Partners GP, L.L.C. (9.99%) and 2 more | 264,510 | 9.99% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BNTC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 11,548,351 | 33.11% | $154.52M | – | 2.83% |
| Nantahala Capital Management, LLC | 2,976,742 | 8.53% | $39.83M | +1,538,371 | 0.66% |
| Jupiter Topco LLC | 2,478,547 | 7.11% | $33.11M | New | 0.01% |
| Franklin Resources Inc | 2,412,888 | 6.92% | $32.28M | +34,729 | 0.01% |
| Adage Capital Partners Gp, L.L.C. | 2,120,672 | 6.08% | $28.37M | – | 0.04% |
| Ra Capital Management, L.P. | 1,850,000 | 5.30% | $24.75M | – | 0.22% |
| BlackRock, Inc. | 1,407,138 | 4.03% | $18.83M | +221,397 | 0.00% |
| Simplify Asset Management Inc. | 1,005,557 | 2.88% | $13.45M | +443,315 | 0.19% |
| Vanguard Capital Management LLC | 954,533 | 2.74% | $12.77M | +22,977 | 0.00% |
| Infinitum Asset Management, LLC | 923,006 | 2.65% | $12.35M | – | 1.26% |
| Millennium Management LLC | 921,299 | 2.64% | $12.33M | +269,235 | 0.00% |
| Alyeska Investment Group, L.P. | 750,000 | 2.15% | $10.04M | – | 0.03% |
| Silverarc Capital Management, LLC | 679,826 | 1.95% | $9.10M | −37,899 | 0.95% |
| Balyasny Asset Management L.P. | 650,503 | 1.86% | $8.70M | −3,332 | 0.01% |
| Geode Capital Management, LLC | 611,736 | 1.75% | $8.19M | +87,632 | 0.00% |
| Ameriprise Financial Inc | 401,245 | 1.15% | $5.37M | −7,525 | 0.00% |
| State Street Corp | 377,973 | 1.08% | $5.06M | +39,724 | 0.00% |
| MYDA Advisors LLC | 250,000 | 0.72% | $3.35M | +25,000 | 0.50% |
| Schonfeld Strategic Advisors LLC | 235,357 | 0.67% | $3.15M | +82,178 | 0.01% |
| AWM Investment Company, Inc. | 187,977 | 0.54% | $2.52M | – | 0.22% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 87 | 35M | 99.4% | 12 / 36 | 22 / 10 | 6M | 0M |
| Q1 2026 | 88 | 32M | 93.1% | 25 / 35 | 13 / 8 | 3M | 1M |
| Q4 2025 | 72 | 32M | 90.8% | 20 / 27 | 15 / 4 | 9M | 1M |
| Q3 2025 | 56 | 23M | 66.4% | 6 / 28 | 9 / 7 | 1M | 0M |
| Q2 2025 | 57 | 23M | 65.0% | 25 / 13 | 12 / 5 | 2M | 1M |
| Q1 2025 | 37 | 22M | 62.8% | 10 / 16 | 6 / 3 | 3M | 0M |
| Q4 2024 | 30 | 19M | 54.5% | 8 / 15 | 4 / 3 | 6M | 1M |
| Q3 2024 | 25 | 14M | 39.3% | 8 / 5 | 8 / 0 | 8M | 0M |
| Q2 2024 | 18 | 6M | 16.4% | 6 / 8 | 2 / 1 | 4M | 0M |
| Q1 2024 | 13 | 1M | 3.7% | 0 / 4 | 2 / 0 | 0M | 0M |
| Q4 2023 | 13 | 1M | 3.4% | 3 / 3 | 1 / 1 | 0M | 0M |
| Q3 2023 | 11 | 1M | 3.6% | 11 / 0 | 0 / 0 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
90 funds held BNTC in Q2 2026, 57% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BNTC | Value | % of fund | As of |
|---|---|---|---|---|---|
| Simplify Health Care ETF | 1,005,557 | 2.88% | $13.45M | 3.75% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 995,152 | 2.85% | $11.65M | 1.01% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 649,542 | 1.86% | $8.69M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 533,504 | 1.53% | $7.14M | 0.01% | Jun 30, 2026 |
| Franklin Small Cap Growth Fund | 357,531 | 1.02% | $4.19M | 0.17% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 281,899 | 0.81% | $3.77M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 233,034 | 0.67% | $2.73M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 188,332 | 0.54% | $2.52M | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 130,966 | 0.38% | $1.51M | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 99,969 | 0.29% | $1.16M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 71,527 | 0.21% | $957.03K | 0.06% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 51,745 | 0.15% | $605.93K | 0.01% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 42,298 | 0.12% | $488.96K | 0.00% | May 31, 2026 |
| Master Small Cap Index Series | 41,853 | 0.12% | $559.99K | 0.01% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 38,625 | 0.11% | $446.51K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Megan Boston | Chief Financial Officer, Director | 25,927 | 0.07% | Nov 20, 2025 |
| Jerel A. Banks | Chief Executive Officer, Director | – | – | Nov 20, 2025 |
| Sophie Mukadam | Chief Operating Officer | 6,016 | 0.02% | Nov 20, 2025 |
| J. Kevin Buchi | Director | 155,723 | 0.45% | Jun 30, 2026 |
| David Matthew Friedman | Director | – | – | May 28, 2026 |
| Sharon Mates | Director | – | – | Jan 26, 2026 |
| Aaron Cowen | Director, 10% owner | 1,848,156 | 5.30% | Dec 29, 2025 |
| Montanova Capital, Llc | Director, 10% owner | 9,538,175 | 27.34% | Dec 29, 2025 |
| Averill Master Fund, Ltd. | Director, 10% owner | 7,920,175 | 22.71% | Dec 29, 2025 |
| Kishan Mehta | Director | – | – | Dec 3, 2025 |
| Edward F. Smith | Director | 0 | – | Dec 3, 2025 |
| Peter Francis | Director | 5,038 | 0.01% | Dec 3, 2025 |
| Averill Madison Master Fund, Ltd. | 10% owner | 1,826,653 | 5.24% | Dec 29, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| J. Kevin Buchi Director | Jun 29, 2026 | Gift | −51,813 | – | – | 52,097 |
| Aaron Cowen Director, 10% owner | Dec 29, 2025 | Buy | +11,587 | $13.44 | $155.73K | 1,848,156 |
| Aaron Cowen Director, 10% owner | Dec 29, 2025 | Buy | +65,800 | $13.44 | $884.35K | 9,700,195 |
| Aaron Cowen Director, 10% owner | Dec 26, 2025 | Buy | +2,516 | $13.10 | $32.96K | 1,836,569 |
| Aaron Cowen Director, 10% owner | Dec 26, 2025 | Buy | +14,320 | $13.10 | $187.59K | 9,634,395 |
| Aaron Cowen Director, 10% owner | Dec 23, 2025 | Buy | +42,600 | $12.85 | $547.41K | 9,620,075 |
| Aaron Cowen Director, 10% owner | Dec 23, 2025 | Buy | +7,400 | $12.85 | $95.09K | 1,834,053 |
| Averill Madison Master Fund, Ltd. 10% owner | Dec 22, 2025 | Buy | +2,892 | $12.08 | $34.94K | 1,826,653 |
| Averill Madison Master Fund, Ltd. 10% owner | Dec 22, 2025 | Buy | +16,650 | $12.08 | $201.13K | 9,577,475 |
| Averill Madison Master Fund, Ltd. 10% owner | Dec 19, 2025 | Buy | +13,950 | $11.48 | $160.15K | 9,560,825 |
| Averill Madison Master Fund, Ltd. 10% owner | Dec 19, 2025 | Buy | +2,434 | $11.48 | $27.94K | 1,823,761 |
| Averill Madison Master Fund, Ltd. 10% owner | Dec 18, 2025 | Buy | +1,515 | $11.24 | $17.03K | 1,821,327 |
| Averill Madison Master Fund, Ltd. 10% owner | Dec 18, 2025 | Buy | +8,700 | $11.24 | $97.79K | 9,546,875 |
| Montanova Capital, Llc Director, 10% owner | Nov 7, 2025 | Buy | +730,370 | $13.50 | $9.86M | 9,538,175 |
| Montanova Capital, Llc Director, 10% owner | Nov 7, 2025 | Buy | +751,111 | $13.50 | $10.14M | 1,819,812 |
| Montanova Capital, Llc Director, 10% owner | Mar 31, 2025 | Buy | +1,267 | $12.63 | $16.00K | 1,068,031 |
| Montanova Capital, Llc Director, 10% owner | Mar 31, 2025 | Buy | +9,503 | $12.63 | $120.02K | 8,802,748 |
| Montanova Capital, Llc Director, 10% owner | Mar 31, 2025 | Buy | +670 | $13.22 | $8.86K | 1,068,701 |
| Montanova Capital, Llc Director, 10% owner | Mar 31, 2025 | Buy | +5,057 | $13.22 | $66.85K | 8,807,805 |
| Aaron Cowen 10% owner | Mar 26, 2025 | Buy | +106,200 | $13.00 | $1.38M | 1,066,764 |
| Aaron Cowen 10% owner | Mar 26, 2025 | Buy | +793,800 | $13.00 | $10.32M | 8,793,245 |
| J. Kevin Buchi Director | Mar 12, 2025 | Gift | +103,626 | – | – | 103,626 |
| J. Kevin Buchi Director | Mar 12, 2025 | Gift | −103,626 | – | – | 284 |
| J. Kevin Buchi Director | Feb 27, 2025 | Option exercise | +51,813 | $3.86 | $200.00K | 103,910 |
| Aaron Cowen 10% owner | Dec 24, 2024 | Buy | +17,730 | $11.25 | $199.46K | 7,999,455 |
| Aaron Cowen 10% owner | Dec 24, 2024 | Buy | +2,288 | $11.25 | $25.74K | 960,554 |
| Aaron Cowen 10% owner | Dec 23, 2024 | Buy | +3,142 | $10.98 | $34.50K | 958,266 |
| Aaron Cowen 10% owner | Dec 23, 2024 | Buy | +24,360 | $10.98 | $267.47K | 7,981,725 |
| Montanova Capital, Llc Director, 10% owner | Dec 3, 2024 | Buy | +37,190 | $9.60 | $357.02K | 7,957,365 |
| Montanova Capital, Llc Director, 10% owner | Dec 3, 2024 | Buy | +4,810 | $9.60 | $46.18K | 955,124 |
| Averill Master Fund, Ltd. Director, 10% owner | Nov 20, 2024 | Buy | +24,360 | $10.22 | $248.96K | 7,920,175 |
| Averill Master Fund, Ltd. Director, 10% owner | Nov 20, 2024 | Buy | +3,076 | $10.22 | $31.44K | 950,314 |
| Averill Master Fund, Ltd. Director, 10% owner | Nov 19, 2024 | Buy | +12,430 | $9.73 | $120.94K | 7,895,815 |
| Averill Master Fund, Ltd. Director, 10% owner | Nov 19, 2024 | Buy | +1,570 | $9.73 | $15.28K | 947,238 |
| Averill Master Fund, Ltd. Director, 10% owner | Sep 26, 2024 | Option exercise | +4,605,000 | $3.86 | $17.78M | 6,663,415 |
| Averill Master Fund, Ltd. Director, 10% owner | Sep 26, 2024 | Option exercise | +588,236 | $1.93 | $1.14M | 2,058,415 |
| Averill Master Fund, Ltd. Director, 10% owner | Sep 26, 2024 | Option exercise | +148,210 | – | – | 945,668 |
| Averill Master Fund, Ltd. Director, 10% owner | Sep 26, 2024 | Option exercise | +576,347 | $3.86 | $2.22M | 797,458 |
| Averill Master Fund, Ltd. Director, 10% owner | Sep 26, 2024 | Option exercise | +1,219,970 | – | – | 7,883,385 |
| J. Kevin Buchi Director | Aug 11, 2023 | Buy | +51,813 | – | – | 52,097 |
| Megan Boston Executive Director | Aug 11, 2023 | Buy | +25,907 | – | – | 25,907 |
| Steven Michael Oliveira 10% owner | Dec 9, 2021 | Buy | +10,553 | $3.04 | $32.08K | 1,000,000 |
| Steven Michael Oliveira 10% owner | Nov 29, 2021 | Buy | +37,947 | $3.18 | $120.67K | 989,447 |
| Steven Michael Oliveira 10% owner | May 3, 2021 | Buy | +40,500 | $4.25 | $172.13K | 951,500 |
| Steven Michael Oliveira 10% owner | Apr 30, 2021 | Buy | +120,000 | $4.18 | $501.60K | 911,000 |
| Steven Michael Oliveira 10% owner | Apr 29, 2021 | Buy | +22,877 | $5.49 | $125.59K | 791,000 |
| Steven Michael Oliveira 10% owner | Apr 28, 2021 | Buy | +100,000 | $5.45 | $545.00K | 768,123 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Benitec Biopharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 49,715 shares on Oct 8, 2026 over the last 90 days.
See a number that looks wrong?